Why the Cure
Isn't the Product.

"They don't want you cured — there's no money in healthy people."

You've heard it. Maybe you've said it. And it's easy to see why: a sick person who needs a pill every day for thirty years is worth far more than a well one. So the suspicion writes itself — somewhere, someone is keeping you sick.

That version is a conspiracy, and like most conspiracies it's both too flattering and too lazy — it imagines a villain with a plan, when the truth is stranger and more useful: there's no villain, no plan, and the effect is real anyway. Nobody has to want you sick for the money to flow toward managing illness rather than ending it. The incentive does that on its own, quietly, through ordinary people doing their jobs well.

Recurring revenue versus a one-shot cure.

In 2018, Goldman Sachs analysts published a report for biotech investors called The Genome Revolution. One line in it became briefly famous, because it said the quiet part in plain numbers. The heading was a question: "Is curing patients a sustainable business model?"[1]

Their worry wasn't moral. It was arithmetic. One-shot cures, they wrote, "offer a very different outlook with regard to recurring revenue versus chronic therapies." A cure sells once. A chronic therapy sells again, and again, for as long as the patient lives. The report even gave a worked example — and it's the cleanest example you'll ever find.

The drug that cured too many people.

Hepatitis C is a virus that slowly scars the liver and, left alone, can end in cirrhosis, liver failure or liver cancer. For decades the treatments were brutal and only sometimes worked. Then, around 2013–14, a new class of pills arrived that genuinely cures it — a short course, few side effects, and the virus is gone for good in more than 95% of people who take it.[2] One of the real triumphs of modern medicine.

And here is what happened to the company that made the market-leading version. Its hepatitis C sales in the United States peaked at about $12.5 billion in 2015 — then fell, by the analysts' own estimate, toward under $4 billion three years later.[1] Not because the drug failed. Because it succeeded. In Goldman's words, "the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients."[1]

Cure the patients, and you run out of patients. The better the cure, the faster the revenue collapses. That's not cynicism — it's the straightforward mechanics of selling something that works once and lasts forever.

It's not about illness. It's about ownership.

Economists have a clumsy word for this: appropriability — how much of the value you create you can actually capture for yourself. A new molecule can be patented, so its maker captures the value and can afford the $1-billion-plus it costs to run the trials that prove it works and get it approved. That's the engine, and it's a genuinely powerful one. It has given us antibiotics, insulin, chemotherapy, vaccines.

But point that same engine at "eat real food, walk every day, sleep, and come off the sugar," and it stalls — not because the advice is wrong, but because nobody can own it. You can't patent a vegetable or a walk. There's no product to sell again next month, no revenue to recoup a trial, and therefore no company willing to spend a billion dollars proving it in the gold-standard way that drugs are proved. The evidence stays thinner, not because the idea is weaker, but because no one on the investor's desk can ever get paid to make it thicker.

When metabolic health is ownable, the money floods in.

If the market were simply biased against treating metabolic disease, the GLP-1 drugs — Ozempic, Wegovy, Mounjaro — would never exist. They do, spectacularly. These are drugs aimed squarely at the metabolic heart of this whole site, and two of them alone brought their maker around $26 billion in a single year.[3] Capital didn't avoid metabolic illness. It stampeded toward it.

Why? Because a GLP-1 drug is the perfect Project B: it's patentable, and you take it indefinitely — the recurring-revenue model in its purest form. That's the tell. The market isn't against metabolic health; it's for ownable, repeatable metabolic health. A drug you inject every week forever is a business. The same metabolic improvement reached by changing what's on your plate is not — even if, for many people, it would get to a similar place.

How far does this actually bend things?

Here's where a good thinking tool has to police itself. Everything above is settled and checkable: the Goldman report exists and said what it said; the hepatitis C revenue curve is real; you can't patent a diet; the GLP-1 numbers are public. That the funding is lopsided is not in serious doubt.

What's harder to pin down is how much that lopsided funding distorts the final picture — how many good root-cause approaches never got their fair trial, how much thinner the lifestyle evidence base is than it would be on a level playing field. That's a reasonable inference, and a worrying one, but it's an inference about a thing that by its nature is hard to measure: you can't easily count the trials that were never run.

This is not a reason to distrust your medicine.

It would be the easiest thing in the world to walk away from this chapter thinking "drugs are a scam, doctors are in on it, I'll stop taking mine." That would be a serious misreading — and a dangerous one.

• The drugs that are on the shelf are, overwhelmingly, there because they passed those expensive trials. The appropriability engine is also the engine that proves things work.
• Your doctor is not an investor. The incentive described here shapes what gets researched and sold at the level of entire industries — not the advice of the person across the desk from you, who is trying to help you with the tools that exist.
• Never stop or change a prescribed medication because of an argument you read on a website. If this chapter makes you want to lean harder on root-cause change, that's a conversation to have with your doctor — many will welcome it — not a reason to go it alone.

No villain. Just a current.

The honest version of "there's no money in healthy people" isn't a conspiracy — it's a current. Money moves, reliably and without malice, toward what can be owned and sold again, and away from what can't. That current has given us genuine cures and genuine wonders, and it has also left the un-ownable interventions under-studied and under-sold. Both things are true at once.

You don't need a villain to explain a river. You just need to know which way it flows — so you can tell when you're being carried, and when you're swimming.